Business Context and Reporting Period
This Form 8-K was filed by 8i Acquisition 2 Corp. (LAX), a British Virgin Islands special purpose acquisition company, regarding a proposed business combination with Euda Health Limited. The report date was May 30, 2022, and it was signed on June 1, 2022.
Under an April 11, 2022 Share Purchase Agreement, LAX agreed to acquire all outstanding shares of Euda Health from Watermark Developments Limited. The transaction would combine LAX and Euda Health; the filing does not itself establish that the transaction was completed.
Financial Metrics and Liquidity
The filing does not provide a clear value for revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity, or other operating financial metrics for LAX or Euda Health.
The filing references a minimum cash requirement under the Share Purchase Agreement following any redemptions by LAX shareholders, but does not state the required amount or available cash balance.
Material Changes Versus the Prior Comparable Period
- On May 30, 2022, the parties amended the Share Purchase Agreement.
- The amendment extended the deadline for LAX to complete its financial, operational, and legal due diligence of Euda Health from May 31, 2022 to June 15, 2022.
- No comparative-period financial results or quantified year-over-year changes are presented.
Guidance, Outlook, Risks, and Unusual Items
No formal financial guidance is provided. The filing includes forward-looking statements regarding the proposed transaction, market opportunity, performance metrics, and anticipated benefits, but cautions that these are based on assumptions and are not guarantees of future performance.
Key transaction risks include failure to complete the Share Purchase, delayed or unavailable regulatory approvals, failure to obtain LAX shareholder approval, failure to satisfy minimum cash conditions after redemptions, inability to obtain a deadline extension, inability to maintain Nasdaq listing, transaction costs, legal proceedings, and adverse findings during due diligence.
Company-specific risks include Euda Health’s limited operating history and history of net losses, execution and growth-management risks, uncertain market acceptance, acquisition-integration challenges, intellectual-property or other litigation, and general economic and market conditions.
LAX and EUDA Health stated that a proxy statement and other transaction-related documents would be filed with the SEC. The furnished press release is not deemed filed for liability purposes under Section 18 of the Exchange Act.
Investor Verification Items
- Verify the final terms of the amended Share Purchase Agreement and whether due diligence was completed by June 15, 2022.
- Review the subsequent proxy statement for transaction consideration, required approvals, shareholder redemption terms, minimum cash requirements, and closing conditions.
- Confirm whether the transaction closed and whether LAX or the combined company maintained its Nasdaq listing.
- Review Euda Health’s audited financial statements for revenue, losses, cash flow, debt, liquidity, and operating history.
- Assess the effect of shareholder redemptions and any financing on the combined company’s post-closing cash position.
- Review the risk factors and subsequent SEC filings for litigation, regulatory issues, delays, or changes to transaction terms.